GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (FRA:G93) » Definitions » Cash Flow from Financing

Jiangsu Recbio Technology Co (FRA:G93) Cash Flow from Financing : €28.49 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Jiangsu Recbio Technology Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2024, Jiangsu Recbio Technology Co paid €0.00 Mil more to buy back shares than it received from issuing new shares. It received €25.50 Mil from issuing more debt. It paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0.00 Mil from paying cash dividends to shareholders. It spent €0.94 Mil on other financial activities. In all, Jiangsu Recbio Technology Co earned €24.57 Mil on financial activities for the six months ended in Dec. 2024.


Jiangsu Recbio Technology Co Cash Flow from Financing Historical Data

The historical data trend for Jiangsu Recbio Technology Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co Cash Flow from Financing Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial 85.53 170.83 113.66 35.35 28.60

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.87 21.65 13.78 4.58 23.91

Jiangsu Recbio Technology Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Jiangsu Recbio Technology Co's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Jiangsu Recbio Technology Co's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €28.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Recbio Technology Co  (FRA:G93) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Jiangsu Recbio Technology Co's issuance of stock for the six months ended in Dec. 2024 was €0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Jiangsu Recbio Technology Co's repurchase of stock for the six months ended in Dec. 2024 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Jiangsu Recbio Technology Co's net issuance of debt for the six months ended in Dec. 2024 was €25.50 Mil. Jiangsu Recbio Technology Co received €25.50 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Jiangsu Recbio Technology Co's net issuance of preferred for the six months ended in Dec. 2024 was €0.00 Mil. Jiangsu Recbio Technology Co paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Jiangsu Recbio Technology Co's cash flow for dividends for the six months ended in Dec. 2024 was €0.00 Mil. Jiangsu Recbio Technology Co received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Jiangsu Recbio Technology Co's other financing for the six months ended in Dec. 2024 was €-0.94 Mil. Jiangsu Recbio Technology Co spent €0.94 Mil on other financial activities.


Jiangsu Recbio Technology Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Recbio Technology Co Business Description

Traded in Other Exchanges
Address
No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.

Jiangsu Recbio Technology Co Headlines

No Headlines